How Much Does Actos (Pioglitazone) Cost in District of Columbia in 2026?

Generic vs. Brand Actos: What DC Residents Actually Pay

The single biggest factor in what you pay for pioglitazone in the District is whether you fill a generic or brand prescription. Brand-name Actos carries a manufacturer list price of $60 per month from Takeda. Generic pioglitazone, available from multiple manufacturers since the patent expired, averages $15 per month at DC retail pharmacies in 2026.

That $15 figure represents an uninsured cash-pay price. With commercial insurance or a pharmacy benefit, your copay could be lower. Some GoodRx-style discount platforms push the price below $10 for a 30-day supply of pioglitazone 30 mg or 45 mg tablets at certain DC pharmacies, including locations in Northwest and Capitol Hill.

Pioglitazone belongs to the thiazolidinedione (TZD) class. The FDA approved it in 1999 for type 2 diabetes as an adjunct to diet and exercise, either as monotherapy or in combination with metformin, sulfonylureas, or insulin. Its mechanism of action involves activation of peroxisome proliferator-activated receptor gamma (PPAR-gamma), which improves insulin sensitivity in adipose tissue, skeletal muscle, and the liver [1]. A 2005 meta-analysis published in JAMA found that pioglitazone reduced HbA1c by 1.0 to 1.5 percentage points compared with placebo across multiple trials [2].

The price gap between brand and generic makes this a relatively accessible diabetes medication. For context, some newer diabetes drugs like SGLT2 inhibitors or GLP-1 receptor agonists cost $800 to $1,200 per month without insurance.

DC Medicaid Coverage for Pioglitazone

District of Columbia Medicaid covers pioglitazone, but you will need prior authorization before the plan pays. This means your prescriber must submit documentation to DC's Medicaid program confirming the clinical need for pioglitazone specifically.

The prior authorization process in DC typically requires evidence that you have tried and failed (or have a contraindication to) metformin, which is the first-line therapy recommended by the American Diabetes Association (ADA) Standards of Care [3]. Once approved, pioglitazone is covered at the preferred generic tier, which means minimal or zero out-of-pocket cost for Medicaid beneficiaries.

DC Medicaid enrollment reached approximately 300,000 residents as of early 2026. If you are enrolled in a Medicaid managed care organization (MCO) such as AmeriHealth Caritas DC or CareFirst Community Health Plan, the prior authorization process routes through your MCO rather than directly through the fee-for-service program. Processing times vary. Most PAs receive a decision within 72 hours.

For the off-label use of pioglitazone in nonalcoholic steatohepatitis (NASH), Medicaid coverage is less predictable. The PIVENS trial (N=247), published in the New England Journal of Medicine in 2010, showed that pioglitazone 30 mg daily significantly improved hepatic steatosis and lobular inflammation compared with placebo in non-diabetic patients with NASH [4]. The American Association for the Study of Liver Diseases (AASLD) practice guidance includes pioglitazone as a pharmacologic option for biopsy-proven NASH [5]. DC Medicaid may require additional clinical documentation for this off-label indication. Your prescriber should include the AASLD recommendation and liver biopsy results in the PA submission.

Which Insurance Plans Cover Pioglitazone in DC?

Most commercial insurance plans sold on DC Health Link (the District's ACA marketplace) cover generic pioglitazone on their formularies. It sits on Tier 1 (preferred generic) for the majority of plans, meaning copays of $0 to $15 per fill.

The major carriers operating in DC include CareFirst BlueCross BlueShield, Kaiser Permanente, and Aetna. Each maintains its own formulary, but generic pioglitazone appears on all of them as of 2026. Brand Actos, by contrast, may require Tier 3 or non-preferred brand copays of $40 to $75.

Federal employees in DC, covered under the Federal Employees Health Benefits (FEHB) Program, also have access to pioglitazone. FEHB plans generally place it at the generic tier. Given that approximately 25% of DC's workforce is federal, this coverage pathway is particularly relevant.

Medicare Part D plans in DC cover pioglitazone as well. Under the Inflation Reduction Act provisions that took effect in 2025, Medicare beneficiaries now have a $2,000 annual out-of-pocket cap on prescription drugs. For a medication costing $15 per month ($180 per year), pioglitazone falls well below this threshold even without supplemental coverage.

Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, stated in 2023: "Thiazolidinediones like pioglitazone remain an important option in our treatment toolkit, particularly for patients who need insulin sensitization and cannot tolerate or afford newer agents" [6].

Compounded Pioglitazone in District of Columbia

Compounded pioglitazone is available through 503A-licensed pharmacies operating in the District of Columbia. A 503A pharmacy compounds medications pursuant to individual patient prescriptions, as permitted under Section 503A of the Federal Food, Drug, and Cosmetic Act.

Why would someone compound a drug that already costs $15 per month as a generic? Two reasons. First, dose customization. Standard pioglitazone tablets come in 15 mg, 30 mg, and 45 mg strengths. A compounding pharmacy can prepare non-standard doses (for example, 7.5 mg or 22.5 mg) if a clinician determines that a patient needs a dose between the commercially available options. Second, formulation changes. Some patients have difficulty swallowing tablets, and a 503A pharmacy can prepare pioglitazone as a suspension or flavored liquid.

DC regulates compounding pharmacies through the DC Board of Pharmacy. Any 503A pharmacy operating in the District must hold a valid DC pharmacy license and comply with USP <795> standards for non-sterile compounding. The DC Board has historically maintained alignment with FDA guidance on compounding, and pioglitazone is not on the FDA's "difficult to compound" list.

Pricing for compounded pioglitazone varies by pharmacy but can range from $0 to $25 per month depending on the formulation complexity and whether the pharmacy participates in discount programs. Some DC compounding pharmacies waive dispensing fees for Medicaid-eligible patients.

Telehealth Prescribing of Pioglitazone in DC

Telehealth prescribing of pioglitazone is fully legal in the District of Columbia. DC was among the first jurisdictions to adopt permanent telehealth parity legislation, and the District's prescribing rules allow clinicians to initiate and manage pioglitazone prescriptions via video or audio-only visits.

Pioglitazone is not a controlled substance, so it does not trigger the DEA's separate telehealth prescribing requirements. Any DC-licensed physician, nurse practitioner, or physician assistant can prescribe it after an appropriate clinical evaluation conducted remotely. The evaluation should include review of recent HbA1c results, liver function tests (ALT and AST), and a clinical assessment for contraindications including active heart failure.

The FDA label for pioglitazone carries a boxed warning regarding congestive heart failure [1]. Specifically, thiazolidinediones cause fluid retention that can exacerbate or precipitate heart failure. Clinicians prescribing via telehealth should confirm that the patient does not have New York Heart Association (NYHA) Class III or IV heart failure before initiating therapy. Baseline and periodic monitoring of weight, edema, and signs of fluid overload are recommended.

Several national telehealth platforms serve DC residents and can prescribe pioglitazone, including HealthRX. The typical workflow involves an asynchronous or synchronous consultation, lab review, and electronic prescribing to a DC pharmacy of the patient's choice.

Discount Programs and Savings Cards for Pioglitazone in DC

Multiple savings pathways exist for DC residents filling pioglitazone prescriptions. The most straightforward is using a pharmacy discount card (GoodRx, RxSaver, or SingleCare) at any participating DC pharmacy. These cards are free, require no insurance, and can reduce the cash price to $4 to $10 for a 30-day supply of generic pioglitazone at chains like CVS, Walgreens, and Rite Aid locations in DC.

Takeda, the manufacturer of brand Actos, has offered savings cards in the past, though their availability and terms change periodically. As of 2026, the brand savings card may reduce copays for commercially insured patients but typically excludes Medicare, Medicaid, and other government-funded insurance. Given that generic pioglitazone costs less than most brand copays, the practical value of a brand savings card is limited for most patients.

DC-specific programs also exist. The DC Department of Health Care Finance administers the DC Healthcare Alliance program, which provides coverage to DC residents who do not qualify for Medicaid, including undocumented immigrants. The Alliance formulary includes generic pioglitazone. Patients enrolled in the Alliance can fill prescriptions at DC pharmacies with no copay for generic medications.

For uninsured patients not eligible for the Alliance, Takeda's patient assistance program (TAP) provides brand Actos at no cost to qualifying individuals with household incomes below 250% of the federal poverty level. Application requires proof of income and a valid prescription.

The 340B Drug Pricing Program also operates in DC. Federally qualified health centers (FQHCs) such as Unity Health Care and Community of Hope can purchase pioglitazone at deeply discounted 340B prices and pass those savings to patients. If you receive primary care at a DC FQHC, ask whether your pharmacy benefits include 340B pricing.

Clinical Considerations: Who Should Take Pioglitazone?

Pioglitazone is FDA-approved for type 2 diabetes but has generated considerable research interest for additional indications. The drug's insulin-sensitizing effects extend beyond glycemic control.

In the PROactive trial (N=5,238), pioglitazone reduced the composite of all-cause mortality, non-fatal myocardial infarction, and stroke by 16% compared with placebo in patients with type 2 diabetes and macrovascular disease, though the primary composite endpoint did not reach statistical significance (P=0.095) [7]. The secondary endpoint of death, MI, and stroke was significant (P=0.027).

The IRIS trial (N=3,876), published in the New England Journal of Medicine in 2016, demonstrated that pioglitazone reduced the risk of stroke or myocardial infarction by 24% in non-diabetic patients with insulin resistance and a recent history of ischemic stroke or transient ischemic attack [8]. This finding, available at PubMed, expanded the clinical conversation around pioglitazone beyond diabetes.

The AASLD guidance recommends pioglitazone as a treatment option for biopsy-confirmed NASH, noting improvements in steatosis, inflammation, and fibrosis scores in the PIVENS trial [4,5]. Dr. Rohit Loomba, Director of the MASLD Research Center at UC San Diego, has noted: "Pioglitazone remains one of the few pharmacotherapies with randomized trial evidence showing histologic improvement in NASH, including resolution of steatohepatitis" [9].

Known risks include weight gain (mean 2 to 4 kg over 6 to 12 months), peripheral edema, and an increased incidence of bone fractures, particularly in postmenopausal women. The FDA safety communication regarding bladder cancer risk was updated after long-term follow-up studies showed no statistically significant association at standard doses [1].

How to Get the Lowest Price on Pioglitazone in DC

A practical approach for DC residents: Start by checking whether you have insurance coverage. If you do, confirm that generic pioglitazone is on your formulary and ask your pharmacy to run your insurance first. If the copay exceeds $15, ask the pharmacist to run a discount card instead.

If you are uninsured, compare prices at three or more DC pharmacies using GoodRx or a similar tool. Costco pharmacies (you do not need a membership to use the pharmacy in DC) and Walmart/Sam's Club locations in the DC metro area often have the lowest cash prices for generics. Independent pharmacies in DC may also offer competitive pricing, particularly those participating in the 340B program.

For Medicaid enrollees, the key step is ensuring your prescriber submits the prior authorization promptly. Delays in PA processing are the most common reason Medicaid patients pay out of pocket unnecessarily. Ask your prescriber's office to submit the PA electronically through the CoverMyMeds platform, which DC Medicaid MCOs accept.

Pioglitazone 30 mg once daily is the most commonly prescribed dose for type 2 diabetes. The 45 mg dose costs roughly the same at the generic level, so dose changes should be driven by clinical response, not cost.